Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

利比韦林 杜鲁特格拉维尔 医学 阿巴卡韦 恩曲他滨 拉米夫定 养生 内科学 病毒载量 人类免疫缺陷病毒(HIV) 抗逆转录病毒疗法 病毒学 乙型肝炎病毒 病毒
作者
Chloe Orkin,Shinichi Oka,Patrick Philibert,Cynthia Brinson,Ayesha Bassa,Д. А. Гусев,Olaf Degen,Juan González‐García,Enrique Bernal,Darrell H. S. Tan,Ronald D’Amico,David Dorey,Sandy Griffith,Shanker Thiagarajah,Marty St. Clair,Rodica Van Solingen‐Ristea,Herta Crauwels,Susan L. Ford,Parul Patel,Vasiliki Chounta
出处
期刊:The Lancet HIV [Elsevier BV]
卷期号:8 (4): e185-e196 被引量:176
标识
DOI:10.1016/s2352-3018(20)30340-4
摘要

Background There is a need for more convenient, less frequent treatment to help address challenges associated with daily oral HIV treatment in people living with HIV, including stigma, pill burden, drug–food interactions, and adherence. The phase 3 ATLAS and FLAIR studies showed non-inferiority of long-acting cabotegravir and rilpivirine dosed every 4 weeks compared with standard oral therapy for the maintenance of virological suppression in adults with HIV-1 over 48 weeks. We present the 96-week findings. Methods FLAIR is a randomised, phase 3, open-label, multicentre study done in 11 countries investigating whether switching to long-acting cabotegravir and rilpivirine is non-inferior to daily dolutegravir, abacavir, and lamivudine in virologically suppressed adults living with HIV-1. Antiretroviral therapy (ART)-naive participants received induction therapy with daily oral dolutegravir (50 mg), abacavir (600 mg), and lamivudine (300 mg) for 20 weeks. After 16 weeks, participants with less than 50 HIV-1 RNA copies per mL were randomly assigned (1:1) to continue the standard of care regimen (standard care group) or switch to receive daily oral cabotegravir 30 mg and rilpivirine 25 mg for at least 4 weeks followed by long-acting cabotegravir 400 mg and rilpivirine 600 mg, administered as two 2 mL intramuscular injections, every 4 weeks for at least 96 weeks (long-acting group). Randomisation was stratified by baseline (preinduction) HIV-1 RNA (<100 000 or ≥100 000 copies per mL) and sex at birth and used GlaxoSmithKline-verified randomisation software (RandAll NG, version 1.3.3) for treatment assignment. The primary endpoint was the proportion of participants with plasma HIV-1 RNA of 50 copies per mL or more assessed as per the US Food and Drug Administration (FDA) Snapshot algorithm at week 48, which has been reported previously. Here, we report the proportion of participants with 50 or more HIV-1 RNA copies per mL using the FDA Snapshot algorithm at week 96 (intention-to-treat population; non-inferiority margin 6%). The trial is registered with ClinicalTrials.gov, NCT02938520. Findings Between Oct 27, 2016, and March 24, 2017, 809 participants were screened. 631 (78%) participants entered the induction phase and 566 (70%) were randomly assigned to either the standard care group (283 [50%] participants) or the long-acting group (283 [50%]). Median age was 34 years (IQR 29 to 43), 62 (11%) were 50 years or older, 127 (22%) were women (sex at birth), and 419 (74%) were white. At week 96, nine (3%) participants in each arm had 50 or more HIV-1 RNA copies per mL, with an adjusted difference of 0·0 (95% CI –2·9 to 2·9), consistent with non-inferiority established at week 48. Across both treatment groups, adverse events leading to withdrawal were infrequent (14 [5%] participants in the long-acting group and four [1%] in the standard care group). Injection site reactions were the most common adverse event, reported by 245 (88%) participants in the long-acting group; their frequency decreased over time. Median injection site reaction duration was 3 days (IQR 2 to 4), and 3082 (99%) of 3100 reactions were grade 1 or 2. No deaths occurred during the maintenance phase. Interpretation The 96-week results reaffirm the 48-week results, showing long-acting cabotegravir and rilpivirine continued to be non-inferior compared with continuing a standard care regimen in adults with HIV-1 for the maintenance of viral suppression. These results support the durability of long-acting cabotegravir and rilpivirine, over an almost 2-year-long period, as a therapeutic option for virally suppressed adults with HIV-1. Funding ViiV Healthcare and Janssen Research and Development.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李爱国的应助被背后小霸王采纳,获得10
1秒前
TEXAS发布了新的文献求助20
2秒前
4秒前
火星上的雨柏完成签到 ,获得积分10
4秒前
5秒前
6秒前
7秒前
7秒前
遂愿完成签到,获得积分10
7秒前
冷静白亦完成签到,获得积分10
8秒前
Nole的应助被俊秀的云朵采纳,获得10
8秒前
英俊的铭的应助被摩登C位采纳,获得10
8秒前
9秒前
旷野发布了新的文献求助10
10秒前
11秒前
00hello00发布了新的文献求助10
11秒前
冷静白亦发布了新的文献求助10
11秒前
kqier发布了新的文献求助10
12秒前
lg完成签到,获得积分10
14秒前
大豆发布了新的文献求助10
14秒前
百事从欢完成签到,获得积分10
14秒前
DW的应助被奇异果采纳,获得10
14秒前
15秒前
15秒前
wanci的应助被树枝采纳,获得10
15秒前
ZZ发布了新的文献求助10
16秒前
17秒前
深情安青的应助被撒拉嘿呀噻采纳,获得10
17秒前
17秒前
高贵的大米完成签到,获得积分10
18秒前
18秒前
18秒前
yyyyy发布了新的文献求助10
18秒前
wmc666发布了新的文献求助10
19秒前
kanraku的应助被彭大采纳,获得10
19秒前
哈哈哈完成签到,获得积分10
20秒前
qq发布了新的文献求助10
21秒前
打打的应助被Lijxuan采纳,获得10
21秒前
幽默玉米发布了新的文献求助10
21秒前
柯米克发布了新的文献求助10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192647
求助须知:如何正确求助?哪些是违规求助? 9579118
关于积分的说明 21863752
捐赠科研通 7792215
什么是DOI,文献DOI怎么找? 3436974
关于科研通互助平台的介绍 2560633
邀请新用户注册赠送积分活动 2483864